Vivus's erectile dysfunction candidate meets goals of first Phase III study
This article was originally published in Scrip
Executive Summary
Vivus's phosphodiesterase-5 inhibitor (PDE-5) avanafil has been shown to improve erectile function in the first of the drug's four pivotal Phase III studies for the treatment of erectile dysfunction (ED).